ALS patient advocate launched the 2014 ice bucket challenge
(CRABURY, N.J. – May 1, 2018) – The National Association of Specialty Pharmacy (NASP), the only national association representing all stakeholders in the specialty pharmacy industry — nation’s leading specialty pharmacies, pharmaceutical and biotechnology manufacturers, health plans and integrated delivery systems — today announces amyotrophic lateral sclerosis (ALS) patient advocate Nancy Frates as their second keynote speaker for the 6th Annual NASP Meeting and Educational Conference, Sept. 24-26. The keynote address will take place Sept. 25 at the Marriott Wardman Park in Washington, D.C.
“We are fortunate to have Nancy as our patient advocacy keynote speaker to share her experiences and challenges. As an organization that strives to enhance patient care, it is important for us to understand the patient journey and the role specialty pharmacy has in optimizing care for all ALS patients, said Mike Agostino, president, NASP.
During her keynote address, “The Impact of Patient Advocacy,” Frates will share her journey as an advocate for the ALS community. She will also delve into her work in Washington, D.C. and discuss the actions governmental authorities can take to enhance ALS research. She will also highlight ways doctors, nurses, patients and families can create a global movement and worldwide awareness for ALS.
After her 27-year-old son Peter was diagnosed with ALS in 2012, Frates dedicated her time to the ALS community by becoming an active advocate and thought activist. As a part of her ongoing efforts, Frates has appeared before Congress, at the White House and before a Food and Drug Administration panel regarding the ongoing challenges faced by the ALS community. Peter, along with the entire Frates family, inspired the viral ALS Ice Bucket Challenge, which raised over $220 million for the ALS Associates and its global partners. Frates continues to educate communities about the disease by speaking at many domestic and international events.
Geared towards the specialty pharmac